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Parkinson’s diseaseAbstract Background: Vitamin D plays an important role in neurodegenerative disorders as a
crucial neuro-immunomodulator. Accumulating data provide evidences that vitamin D receptor
(VDR) gene is a candidate gene for susceptibility to Parkinson’s disease (PD).
Aim: To ﬁnd out whether the risk of the development of sporadic PD might be inﬂuenced by
VDR gene polymorphisms in an Iranian population or not.
Subjects and methods: A genetic study was conducted to investigate the relationship between
VDR gene polymorphisms and the severity of PD. Fifty-nine PD patients and 53 matched-
healthy controls were genotyped using polymerase chain reaction–restriction fragment length poly-
morphism (PCR–RFLP) analysis. For this purpose, four single nucleotide polymorphisms (SNPs)
in VDR gene including FokI T > C (rs 10735810), BsmI A > G (rs 1544410), ApaI A > C (rs
7975232), and TaqI C > T (rs 731236) have been evaluated.
Results: Our genotyping studies revealed that holding ApaI a allele and FokI f allele could sig-
niﬁcantly increase the risk of developing Parkinson’s disease 1.85 and 2.46 times, respectively
(p= 0.023 and 0.008). Moreover, Aa heterozygous of ApaI also shows a signiﬁcantly elevated risk
of developing PD when compared to AA homozygous (OR = 7.44, p= 0.005). For BsmI and TaqI
polymorphisms, no signiﬁcant difference in genotype or allele distribution was found between PD
patients and the controls. Moreover, in this study, no signiﬁcant association was found between dif-
ferent genotypes and Hoehn & Yahr staging and Uniﬁed Parkinson Disease Rating Stage (UPDRS)
rating scale.//dx.doi.
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org/10.1016/j.ejmhg.2016.08.004Conclusion: This study demonstrates a possible association between the VDR FokI and ApaI
polymorphism and PD, indicating that VDR polymorphisms may change genetic susceptibility to
sporadic PD in the Iranian population.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson’s Disease (PD) is known as the most common neu-
rodegenerative movement disorder in elderly people [1].
Recently, vitamin D3 has been suggested as an environmen-
tally modiﬁable factor, effective in the pathogenesis of PD
[2]. A signiﬁcantly lower 25-hydroxyvitamin (25OH) D levels
were observed both in Caucasian [3] and Japanese patients
with more severe PD [4,2]. On the other hand, expression of
vitamin D receptor (VDR) is tremendously high in neurons
of the substantia nigra, where dopaminergic neurons are selec-
tively lost in PD [5]. In previous studies, besides the neuropro-
tective effects of vitamin D3 on cells of the nervous system [6],
there were some epidemiological evidences conﬁrming the
potential value of vitamin D in PD prevention [7,2].
However, multiple genetic studies have revealed an associ-
ation between the risk of PD with polymorphism in the
VDR gene [2,8,9], although the results are conﬂicting [10].
Based on genome-wide association studies, the correlations
between VDR polymorphisms and both risk and age at the
onset of PD have been investigated in a Caucasian population
[2,9]. Moreover, overexpression of the BsmI A>G (rs
1544410) polymorphism was reported among Korean PD
patients [8]. Recent studies have shown a signiﬁcant correla-
tion between VDR FokI T > C (rs 10735810) genotype and
PD in the Japanese and Chinese Han populations [2,11]. In
contrast to these results, Petersen et al. found no difference
in genotype (ApaI A> C (rs 7975232), BsmI, TaqI C> T
(rs 731236)) frequencies between PD cases and controls in
the VDR polymorphisms in Faroe Island [12].
Previous data have shown that genetic variation in VDR
gene could induce serious defects of receptor activation by
altering the afﬁnity of the receptor to vitamin D [13]. However,
there has been no report on the severity of PD and vitamin D
gene variants in the Iranian population. Hence, a genetic study
was conducted to investigate the relationship between VDR
gene polymorphisms and both risk and severity of PD.
2. Subjects and methods
2.1. Patient selection for genetic analysis
The case–control study of the Iranian PD patients was con-
ducted during September to November 2011, as it has been
previously described [14,15]. The people gave an informed con-
sent and agreed to participate in the current study. The ethics
committee of the Isfahan University of Medical Sciences
approved the protocol for this study. It was according to
Declaration of Helsinki.
All PD cases were examined clinically by the same
experienced neurologist according to the United Kingdom
Parkinson’s Disease Brain Bank criteria [16]. Then, the Hoehn
and Yahr scale (H&Y) was used for clinical staging accordinget al., Vitamin D receptor gene variantsto four stages of 1–1.5, 2–2.5, 3, and 4–5 [17] as well as the
motor part of the Uniﬁed Parkinson’s Disease Rating Scale
III (UPDRS III) [18]. Exclusion criteria included having a his-
tory of taking vitamin D or being diagnosed to have familial
background or early onset of PD (<40 years old) and lack
of voluntary participation for DNA extraction. Finally, 59
PD patients and 53 age-sex matched controls were chosen
for genetic analysis.
After receiving consent from patients and controls, a blood
sample was taken and DNA was isolated using a standard salt-
ing out procedure. The presence of the VDR FokI T > C (rs
10735810), BsmI A > G (rs 1544410), ApaI A > C (rs
7975232), and TaqI C > T (rs 731236) SNPs were identiﬁed
by polymerase chain reaction–restriction fragment length poly-
morphism (PCR–RFLP) according to the manufacturer’s
instructions. The primer information including their annealing
temperature, PCR product length before and after the diges-
tion and the exact position of ampliﬁcation is listed in Table 1.
DNA fragments were separated in 2% agarose gels and
visualized by Gel Red staining. The presence of the FokI
T > C (rs 2228570), BsmI G > A (rs 1544410), ApaI C > A
(rs 7975232), and TaqI T > C (rs 731236) polymorphisms
was also conﬁrmed by repeated PCR–RFLP analysis. Allelic
nomenclature of dominant (FBAT) alleles is based on endonu-
clease success over its restriction sites FokI, BsmI, ApaI and
TaqI. In view of that, recessive (fbat) alleles were used when
the above restriction endonucleases fail to cut their corre-
sponding DNA molecules.
2.2. Statistical analysis
Statistical analysis was carried out using online SISA software
available at: http://www.quantitativeskills.com/sisa/index.htm.
p-values less than 0.05 were considered statistically signiﬁcant
and odds ratios (OR) with 95% conﬁdence intervals (95% CI)
were calculated to judge the correlations between speciﬁc fac-
tors and the risk of developing PD.
3. Results
Allelic comparison of four polymorphic sites of VDR illus-
trated that Apa-I (a) and Fok-I (f) recessive alleles were very
signiﬁcantly related to the risk of developing PD (Table 2).
As indicated in Table 2 and 51% of PD patients carry a allele,
while only 36% of control individuals hold that allele. The
same results were also recorded for Fok-I as 28.8% of Parkin-
son’s disease patients carry f allele and only 14.1% of healthy
individuals carry the same allele. As depicted in Table 2, hold-
ing a allele and f allele could signiﬁcantly increase the risk of
developing PD by 1.85 and 2.46, respectively (p value = 0.023
and 0.008).
Based on the signiﬁcant allelic relationship, further analysis
on genotypes was encouraged. As expected from allelicin Parkinson’s disease patients, Egypt J Med Hum Genet (2016), http://dx.doi.
Table 1 Characterizations, conditions and primers of vitamin D receptor (VDR) gene polymorphisms.
SNP dbSNP# Position Alleles Primer (50–30) PCR
Product
(bp)
Annealing
temp.(C)
Restriction
fragment
length (bp)
FokI rs2228570/
rs10735810
Exon 2 C/T F: GCACTGACTCTGGCTCTGAC 341 72.5 C(F) = 341
(F/f) R: ACCCTCCTGCTCCTGTGGCT T(f) = 282 + 59
BsmI rs1544410 Intron 8 A/G F: GGAGACACAGATAAGGAAATAC 248 60 A(B) = 248
(B/b) R: CCGCAAGAAACCTCAAATAACA G(b) = 175 + 73
ApaI rs7975232 Intron 9 A/C F: AGCAGAGCAGAGTTCCAAGC 701 58 A(A) = 701
(A/a) R: GTGAGGAGGGCTGCTGAGTA C(a) = 246
+ 455
TaqI rs731236 Exon 9 T/C F: AGCAGAGCAGAGTTCCAAGC 701 58 T(T) = 701
(T/t) R: GTGAGGAGGGCTGCTGAGTA C(t) = 523 + 178
Vitamin D receptor gene variants 3frequencies, being aa homozygote elevates the risk of develop-
ing PD nine times as compared to AA homozygous
(OR= 9.15, p= 0.004). On the other hand, Aa heterozygous
also shows a signiﬁcant elevated risk of developing Parkinson’s
disease, when compared to AA homozygous (OR= 7.44,
p= 0.005). Parallel to Apa-I, Fok-I homozygous ff and
heterozygous Ff genotypes also demonstrate a non-signiﬁcant
relationship, as being ff and Ff could increase the risk of devel-
oping PD 3.84 and 1.50 times, respectively (Table 2).
Further analysis has been conducted based on VDR gene
polymorphisms and Vitamin D serum levels to explore the pos-
sible relationships between different genotypes and serum
levels of vitamin D in patients and control (Table 3). As illus-
trated in Table 3, none of our singular VDR gene polymorphic
sites showed any kind of relationship with vitamin D serum
levels. Likewise, no signiﬁcant relationship was found between
different genotypes and H&Y staging or UPDRS rating when
evaluating the correlation of VDR gene polymorphisms and
the severity of PD (Table 4).4. Discussion
In a population based case–control comprehensive study, the
severity of PD and vitamin D gene variants including FokI,
BsmI, TaqI, and ApaI has been accomplished in the Iranian
population. Our preliminary data had shown that FokI genetic
variation in VDR gene may increase the risk of PD develop-
ment in the local population in our country [19].
In our recent study, some positive results in polymorphisms
of vitamin D-related genes were obtained. Among the four
kinds of VDR SNPs, the FokI/f allele and ApaI/aa genotypes
showed a strong association with risk of PD. It must be also
mentioned that there are some positive results that could cor-
relate the polymorphisms of VDR genes to PD development
[9,11,8,2,20]. The only study assessing the ApaI genotypes in
relation to PD [2] conﬁrmed our ﬁnding. The ApaI polymor-
phism was associated with the early-onset of PD in the
American Caucasian population [9]. According to our results,
holding f allele in FokI genotype might increase the risk of PD
development up to 2.5-fold. In concordance to our ﬁnding,
FokI FF genotype was accompanied by milder forms of PD
in Japan [2]. Unlike these ﬁndings, in Hungarian and Chinese
populations, the frequency of F allele was signiﬁcantly higher
in PD patients [5]. As indicated before, FokI polymorphismPlease cite this article in press as: Meamar R et al., Vitamin D receptor gene variants
org/10.1016/j.ejmhg.2016.08.004as a 5’UTR polymorphic site can cause different translation
initiation in the subsequent VDR gene [21]. Subsequently,
the length of protein would be three amino acids shorter in
F allele and it may induce changes in VDR function. Accord-
ing to Arai et al. [22], if the VDR gene contains F allele, it
results in better intestinal calcium absorption compared to f-
VDR. Based on the relation between serum hormone levels
and PD [7], it has supposed that f allele may predict lower
serum vitamin D levels and consequently higher risk for PD
[11]. This is in complete accordance with the ﬁndings of the
present study.
Consistent with our ﬁndings, no association between BsmI
polymorphism and PD was found by Suzuki et al. and Han
et al. [2,11]. In contrast, one report has been shown an associ-
ation between BsmI polymorphism and PD development [8].
Lastly, the TaqI polymorphism was not correlated with PD
in our study, which conﬁrms the ﬁndings of previous studies
[2,10,9]. A Meta-analysis also conﬁrms this proposition,
detecting no association between ApaI, BsmI, and TaqI poly-
morphisms and PD susceptibility in its all four genetic models
[10]. In addition, according to four genetic models in East
Asian subgroup, a signiﬁcant correlation was observed
between ApaI polymorphism and PD susceptibility [10].
Whereas, BsmI, ApaI and TaqI polymorphisms are located
in the 30 region of the VDR gene and consequently no alter-
ation in the amino acid sequence of the encoded protein has
been assumed. Therefore, these polymorphisms may not alter
the structure or the function of the VDR protein [23].
The differences in the results, found by various authors,
could be clariﬁed with regard to the study populations, sample
sizes, and ethnic variations. On the other hand, the data diver-
sity in the Caucasian population suggests that this population
is not homogeneous.
In our previous study, we have compared biochemical levels
which are related to bone metabolism, between PD patients
and age-matched healthy controls [15]. As the ﬁrst study in
the Middle East population, no signiﬁcant difference in
25OHD was found between PD patients and control group
[15]. Low vitamin D level is probably a common problem in
Iranian population. Also, in our previous study, a high preva-
lence of 25OHD insufﬁciency (72.8%) and deﬁciency (38.4%)
was reported among Iranian parkinsonism [14]. Although a
correlation was found between PD risk and ApaI in this study,
no association was found between ApaI and 25(OH) D levels.
In a study performed in Faroese island, subjects within Parkinson’s disease patients, Egypt J Med Hum Genet (2016), http://dx.doi.
Table 2 Association between Vitamin D receptor polymorphisms and risk of developing Parkinson’s disease.
SNP PD patients (%) Control (%) Odd ratio (95% CI) Pearson (p-value) Overall Pearson (p-value)
ApaI AA 14 (23.7) 2 (3.8) 1 7.21 (0.027)
Aa 32 (54.3) 34 (64.2) 7.44 (1.57–35.33) 6.37 (0.012)
aa 13 (22) 17 (32) 9.15 (1.76–47.58) 6.93 (0.008)
a 60 (51) 38 (36) 1.85 (1.08–3.17) 5.10 (0.023)
A 58 (49) 68 (64)
BsmI BB 24 (40.7) 17 (32.1) 1 0.891(0.640)
Bb 27 (45.8) 28 (52.8) 1.46 (0.65–3.31) 0.84 (0.360)
bb 8 (13.5) 8 (15.1) 1.41 (0.44–4.51) 0.34 (0.560)
b 75 (63.6) 62 (58.5) 1.24 (0.72–2.12) 0.60 (0.440)
B 43 (36.4) 44 (41.5)
FokI FF 6 (10.2) 2 (3.8) 1 6.27(0.043)
Ff 22 (37.3) 11 (20.8) 1.50 (0.26–8.69) 0.21 (0.651)
ﬀ 31 (52.5) 40 (75.5) 3.87 (0.73–20.51) 2.53 (0.112)
f 34 (28.8) 15 (14.1) 2.46 (1.25–4.83) 7.03 (0.008)
F 84 (71.2) 91 (85.9)
TaqI tt 28 (47.5) 23 (43.4) 1 0.26(0.878)
Tt 25 (42.4) 26 (49.1) 1.22 (0.56–2.66) 0.24 (0.622)
TT 6 (10.1) 4 (7.5) 1.01 (0.27–3.76) 0.00 (0.983)
T 81 (68.6) 72 (67.9) 1.03 (0.59–1.82) 0.01 (1)
t 37 (31.4) 34 (32.1)
PD: Parkinson’s disease; CI: conﬁdence interval.
Table 3 Association of Vitamin D receptor polymorphisms with the vitamin D3 serum concentration between Parkinson’s disease
patients and controls.
SNP Genotype VitD3 PD (Mean ± SD) VitD3 Controls (Mean ± SD) Odd Ratio (95% CI) Pearson (p-value)
ApaI AA 30.71± 13.64 32.50± 23.33 1
Aa 34.33± 16.98 30.44± 12.79 0.84 (0.42–1.68) 0.25 (0.62)
aa 28.10± 10.04 26.50± 14.22 0.89 (0.43–1.84) 0.10 (0.76)
BsmI BB 32.29± 15.31 27.88± 10.69 1
Bb 36.09± 16.81 28.85± 12.71 1.12 (0.57–2.23) 0.11 (0.74)
bb 30.94± 10.56 35.00± 22.68 0.99 (0.48–2.08) 0 (1)
FokI FF 29.22± 13.73 26.50± 13.43 1
Ff 34.10± 15.15 27.73± 10.78 0.90 (0.43–1.85) 0.09 (0.77)
ﬀ 31.27± 15.56 29.86± 14.37 1.05 (0.51–2.18) 0.02 (1)
TaqI tt 33.81± 15.96 32.14± 16.23 1
Tt 30.99± 15.17 26.61± 10.78 0.90 (0.45–1.83) 0.08 (0.78)
TT 30.10± 1.30 28.80± 10.00 1.00 (0.50–2.03) 0 (1)
PD: Parkinson’s disease; CI: conﬁdence interval.
4 R. Meamar et al.heterozygous genotype in ApaI showed signiﬁcantly higher 25
(OH)D values compared to the two homozygous genotypes
[12]. Suzuki et al. did not ﬁnd any association between ApaI
or the other VDR genotypes and vitamin D levels among the
Japanese patients [2]. However, as the genotype distribution
varies among different ethnicities, it is not unexpected that
our results are more concordant with Susuki’s ﬁndings in an
Asian population. According to the previous documents that
have considered ApaI as a silent polymorphism, larger studies
in different ethnic populations are required to assess the pre-
cise implication.
In the previous report, we obtained no association between
the 25OHD levels and HY stages, UPDRS III even after mul-
tivariate adjustment for possible confounders in Iran [14]. InPlease cite this article in press as: Meamar R et al., Vitamin D receptor gene variants
org/10.1016/j.ejmhg.2016.08.004accordance to our previous study, we found no signiﬁcant rela-
tionship between different genotypes and HY staging or
UPDRS rating. To conclude, none of our singular VDR gene
polymorphic sites showed any kind of relationship with Vita-
min D serum levels.
Prior to this study, only one paper has been published to
include both VDR polymorphisms and circulating 25(OH) D
levels [2]. However, focusing on the severity of PD, Suzuki
et al. found that higher levels of 25(OH) D were signiﬁcantly
associated with lower HY stages and lower UPDRS scores
[2]. The reason for this inconsistency may be attributed to
the smaller number of patients with advanced PD in our study.
The mean HY stage was 1.8 in the current study, which is
lower than the same value in Suzuki’s study (2.4) [2]. Also, thisin Parkinson’s disease patients, Egypt J Med Hum Genet (2016), http://dx.doi.
Table 4 Association of Vitamin D receptor polymorphisms sites and severity of Parkinson’s disease according to H&Y scale and
UPDRS.
SNP Genotype HY stages p-Value UPDRS
OR 95%CI Coeﬃcient p-Value
ApaI AA 1 Reference
Aa 0.77 1.45 to 0.93 0.67 0.022 0.84
aa 0.50 2.10 to 0.71 0.33 0.121 0.26
BsmI BB 1
Bb 0.50 2.16 to 0.78 0.358 0.183 0.18
bb 0.53 2.12 to 0.86 0.406 0.082 0.55
FokI FF 1
Ff 1.39 0.68 to 1.34 0.52 0.26 0.196
ﬀ 1.08 1.53 to 1.69 0.92 0.16 0.430
TaqI tt 1
Tt 0.45 2.47 to 0.87 0.348 0.11 0.48
TT 0.43 2.50 to 0.81 0.317 0.12 0.47
Hoehn &Yahr: H&Y; UPDRS: Uniﬁed Parkinson’s Disease Rating Stage; CI: conﬁdence interval.
Vitamin D receptor gene variants 5study reported no interaction between FokI and ApaI VDR
gene on the severity of PD [2], similar to the ﬁndings of the cur-
rent research.
This study, carried out for the ﬁrst time in central Iranian
subpopulation, revealed the role of VDR gene polymorphisms
in increasing the risk of developing PD. In conclusion, Aa
homozygosity for the ApaI genotype and FokI f allele are
genetic risk factors for PD.
Also, some limitations of this study need to be enounced:
First, the study population was small; hence, we could not gen-
eralize the obtained results to the overall population. Second,
selection of healthy controls was signiﬁcant, because choosing
fully matched controls with cases is very important. Neverthe-
less, the exact association between VDR gene polymorphisms
and risk of PD cannot be opined and more research is required
for better clariﬁcation.
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